DOT-UBQ-Header


The ubiquitin proteasome system (UPS) is an essential and highly regulated mechanism operating to tightly control intracellular protein degradation and turnover. Recently, researchers have found new ways to chemically modulate this cellular machinery, thereby altering protein homeostasis as a therapeutic strategy to achieve phenotypic novelty and providing new avenues for pharmacological development. In particular, specific components of the UPS, such as E3 ligases, deubiquitinases (DUBs) and ubiquitin-like protein (Ubl) activating enzymes are quickly emerging as promising targets as they provide specificity for targeting with the ability to alter cellular processes within a wide range of disease indications. As new strategies and tools emerge, novel UPS inhibitors are rapidly being developed and are collectively setting the foundation for a new generation of therapeutics. 

Cambridge Healthtech Institute’s Third Annual Targeting the Ubiquitin Proteasome System will once again gather an interdisciplinary collection of leaders working to advance the rapidly expanding field of UPS drug discovery.

Who should attend: Executives, Directors, Managers, Researchers, and Scientists from Pharma, Biotechs, Academia, Government and Healthcare Organizations working in fields such as Oncology, Molecular/Cell Biology, Biochemistry, Chemical Genomics/Biology, Structural Biology, Medicinal Chemistry, Synthetic Chemistry and Protein Engineering

Topics will include, but are not limited to: 

  • Ubiquitin Biology
    • Novel Roles of Ubiquitin Chains and Modifications
    • Elucidation and Characterization of Cellular Functions/Regulatory Mechanisms
    • Deregulation of Ubiquitin Ligases and DUBs in Human Cancers, Neurodegenerative Diseases, and Inflammation
    • Technological Advances for Interrogating the Ubiquitin Proteasome System
  • Small-Molecule Chemistry and Drug Development Approaches
    • Identification of Novel Probes (di‐Ub) and Inhibitors
    • Novel Small-Molecule Approaches for Targeting the Ubiquitin Cascade: E2, E3 and DUBs
      • Emphasis on RING E3 ligases, deubiquitinases (DUBs) and ubiquitin-like protein (Ubl) activating enzymes 
       
    • Chemical Genomic and High-Throughput Screening Strategies
    • DUB Ub‐linkage Inhibitor Screening
    • Ubiquitin Variants and Protein Engineering for Discovery
  • Target Validation
    • Chemical Proteomics and Mass Spectrometry for Inhibitor Profiling
    • In vivo Efficacy and Toxicity Studies

If you are interested in speaking, click here to submit a speaking proposal.

The deadline for submission is March 11, 2015. 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For questions or suggestions about the meeting, please contact:
Kip Harry
Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5454
E: kharry@healthtech.com 

For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Jon Stroup
Sr. Business Development Manager
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

DOT Hub Icon 

2014 Discovery on Target Brochure  

2014 BROCHURE 

PREMIER SPONSORS 

Cellecta 

Molecular Sensing
 

VIEW ALL SPONSORS 

VIEW MEDIA PARTNERS 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2014, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Jon Stroup
Sr. Business Development Manager
781-972-5483
jstroup@healthtech.com 


Westin Boston Waterfront

HOTEL & TRAVEL 

Westin Boston Waterfront
425 Summer Street
Boston, MA 02210
617.426.2000